S. Pabel, S. Wagner, H. Bollenberg
Oct 17, 2018
Citations
8
Influential Citations
143
Citations
Quality indicators
Journal
European Journal of Heart Failure
Abstract
Empagliflozin, a clinically used oral antidiabetic drug that inhibits the sodium‐dependent glucose co‐transporter 2, has recently been evaluated for its cardiovascular safety. Surprisingly, empagliflozin reduced mortality and hospitalization for heart failure (HF) compared to placebo. However, the underlying mechanisms remain unclear. Therefore, our study aims to investigate whether empagliflozin may cause direct pleiotropic effects on the myocardium.